510(k) device
Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio
Fujirebio Diagnostics,Inc. · Immunoassay Blood Test For Amyloid Pathology Assessment (SET, Class II) · First FDA decision May 16, 2025, newest May 16, 2025Alzheimer's disease and dementia
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "Lumipulse G pTau217"
MAUDE reports
0
Brand "Lumipulse G pTau217", since 2015
PubMed studies
0
Mentioning "Lumipulse G pTau217"
AI summary across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Lumipulse G pTau217/ß-Amyloid 1-42 Plasma RatioBreakthrough510(k)
K242706 · Decided May 16, 2025 · 249 days after receipt
Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Screening Immunoassay Fecal-Occult Blood TestNational analysisReview closedCAG-00180NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Lumipulse G pTau217", any status and sponsor, newest update first.
No registered device study names "Lumipulse G pTau217".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Lumipulse G pTau217", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SET
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1301-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1302-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1303-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1304-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1305-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1306-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Z-1307-2026 · Started Dec 11, 2025 · Posted by FDA Feb 5, 2026
Reason given: Customers may experience inaccurate test results by observing a higher frequency of classification in the indeterminate and positive zone and/or low specificity when compared back to FDA-cleared CSF ratio/PET imaging, due to falsely elevated positive ratio or falsely elevated indeterminate ratio results causing an...
Cause as FDA categorized it: Under Investigation by firm · Device type: Immunoassay Blood Test For Amyloid Pathology Assessment (SET)
Published research
The most relevant PubMed records for "Lumipulse G pTau217"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code SET.
- Elecsys Phospho-Tau (217P) PlasmaRoche Diagnostics · 510(k) 2026
- PrecivityAD2 TestC2N Diagnostics, LLC · 510(k) 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.